Clinical trials
Other Cancer clinical trials
Below are recruiting other cancer clinical trials, each written for real people, not researchers. We’re tracking 12,865 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07838519Enrolling by invitation
Personalized lung cancer screening for veterans
This study tests a personalized approach to help veterans decide if lung cancer screening is right for them. It aims to improve early detection by considering each person's unique risk factors, such as smoking history, military exposures, and lung health.
Aurora, ColoradoAges 50–80 - NCT07827001Recruiting
Monitoring brain tumors during systemic treatment
This study tests whether it's safe to skip radiation and instead rely on a new systemic treatment (like immunotherapy or targeted therapy) to control brain tumors that have spread from other parts of the body. It might help you manage your disease while avoiding the side effects of radiation.
Orange, CaliforniaAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT05341492RecruitingEarly Phase 1
CAR-T therapy for EGFR/B7H3-positive lung and triple-negative breast cancer
This early-phase trial tests CAR-T cells designed to find and attack tumors that show EGFR or B7H3 markers. It may help people with advanced lung cancer or triple-negative breast cancer after standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06196294RecruitingPhase 1
Engineered immune cells for cancers with GPC3 or mesothelin
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07820566Recruiting
Personalized 3D tumor model for kidney, bladder, and prostate cancers
This study uses your tumor sample to build a personalized 3D model that mimics how your cancer grows. The goal is to better understand these cancers and potentially find more effective treatments in the future.
StrasbourgAges 18 years+ - NCT07813637RecruitingPhase 1
Testing a combination of two new drugs for advanced prostate cancer
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
Nashville, TennesseeAges 18 years+ - NCT05855811RecruitingPhase 2
Preventing a Second Cancer After Your First Cancer
This Phase 2 trial tests dostarlimab, an immune-based medicine, to help lower the chance of getting a second (new) cancer after treatment for a first solid tumor. It’s for people with higher risk features, and it aims to see whether the drug can prevent or delay second cancers.
CaenAges 18 years+ - NCT05504772Recruiting
Personalized genetic testing for children with cancer
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
AdelaideAges birth–25 years - NCT07788196RecruitingPhase 2
Adding anti-HER2 therapy after surgery for early-stage gastric cancer
This trial tests whether adding a targeted therapy (anti-HER2) to standard chemotherapy after surgery can improve outcomes for people with early-stage gastric cancer that has high HER2 levels. It aims to see if the combination is more effective than chemotherapy alone.
Xi'an, ShaanxiAges 18 years+ - NCT06543108Recruiting
Comparing two PET scans for stomach cancer
This study compares two types of PET scans (FAPI and FDG) to see which one works better for diagnosing stomach cancer. You would receive both scans within a week, and your doctor would also check your blood for tumor markers.
Changsha, HunanAges 18–90 - NCT07776691RecruitingPhase 3
Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Washington D.C., District of ColumbiaAges 18 years+ - NCT07776613RecruitingPhase 2
Bone strengthening drug for breast cancer with osteoporosis
This study tests a new drug called romosozumab, which may help strengthen bones and reduce fractures in people with breast cancer that has spread to the bones and who also have osteoporosis. If you are on hormone therapy and have weak bones, this could help protect your bones.
Basking Ridge, New JerseyAges 18 years+ - NCT07779109Recruiting
Shorter radiation course for endometrial cancer after surgery
This study tests a shorter, more intense course of radiation therapy after surgery for endometrial cancer. It aims to see if it is safe and works as well as standard radiation, while possibly reducing treatment time.
Zaragoza, ZaragozaAges 18–110 - NCT07768436RecruitingPhase 2
cmf chemotherapy for breast cancer in older adults
This trial tests a combination of three older chemotherapy drugs (cyclophosphamide, methotrexate, and fluorouracil, called CMF) for adults 70 and older with breast cancer. The goal is to see if this treatment is effective and well-tolerated in this age group.
Basking Ridge, New JerseyAges 70 years+ - NCT07764497RecruitingPhase 2
Chemotherapy through liver artery for colorectal cancer that spread to liver
This trial tests giving chemotherapy directly into the liver artery for people whose colorectal cancer has spread only to the liver and cannot be surgically removed. The goal is to shrink the tumors and make the liver healthy enough for surgery.
Toronto, OntarioAges 18 years+ - NCT06589388Recruiting
Using a blood test to predict rectal cancer treatment success
This trial is looking at whether a simple blood test (ctDNA monitoring) can help predict how well total neoadjuvant therapy (chemo and radiation before surgery) works for rectal cancer. It may help doctors tailor treatment to your specific needs.
Ho Chi Minh CityAges 18–80 - NCT06609551RecruitingPhase 3
ctDNA-guided chemo choice for elderly colon cancer patients
This trial tests whether using a ctDNA blood test can help choose the best chemotherapy after colon cancer surgery for people aged 70–80. It aims to make treatment more personalized and reduce side effects.
Hangzhou, ZhejiangAges 70–80 - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT07747740RecruitingPhase 2
Bladder cancer treatment after BCG therapy fails
This trial compares two combinations of chemotherapy drugs given directly into the bladder to see which works better for patients whose bladder cancer has not responded to BCG therapy.
Moscow, MoscowAges 18 years+ - NCT07734389Recruiting
Genetic breast cancer risk test for DORA study participants
This trial offers genetic testing to women who took part in the earlier DORA study and were found to have a moderately increased or high risk of breast cancer. It aims to better understand genetic risk factors to improve early detection and prevention.
LjubljanaAges 53–54 - NCT07735624RecruitingPhase 2
Immunotherapy before surgery for early rectal cancer
This trial tests a combination of two immunotherapy drugs (botensilimab and balstilimab) given before surgery for early-stage rectal cancer that is MSS/pMMR. The goal is to see if this treatment can shrink the tumor and improve outcomes compared to standard care.
Boston, MassachusettsAges 18 years+ - NCT07732491RecruitingPhase 2
Culmerciclib for HR+ HER2+ advanced breast cancer
This study tests a new drug called Culmerciclib for women with a certain type of advanced breast cancer that has both hormone receptors and HER2. It’s for patients whose cancer has been stable on at least 4 cycles of prior therapy.
Guangzhou, GuangdongAges 18 years+ - NCT05594095RecruitingPhase 2
Study for advanced ER+ HER2− breast cancer after CDK4/6 therapy
This Phase 2 trial tests an investigational “SNF platform” treatment for advanced ER+ (estrogen-receptor positive) and HER2− breast cancer in people who already tried CDK4/6 inhibitor therapy. It may help shrink tumors and improve outcomes for cancers that have come back or spread.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Other Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for other cancer?
- Yes. Clin2 currently lists 12,865 recruiting other cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a other cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a other cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.